AsepticSure Receives EU Patent Approval For its Bio-Terrorism Counter Measures Application

San Francisco, California, June 13, 2016 – Medizone International, Inc. (OTCQB: MZEI) is pleased to announce that its unprecedented room disinfection technology, AsepticSure®, has been granted patent protection by the European Union Patent and Trademark Office (EU) for its patent application Bio-Terrorism Counter Measures Using Ozone and Hydrogen Peroxide. The European Patent Office awarded patent number 252583B to this application, which provides a government counter measures response to a biological attack.

Medizone already has a significant number of applications granted for its disinfection technology for health care and sports facility disinfection. To date, AsepticSure has demonstrated a greater than 6-log kill (>99.9999% kill) against all bacterial and viral pathogens it has been tested against. This EU patent grant expands on the previously awarded bio-terrorism patent protection as awarded in the United States and Canada. With this EU patent, Medizone secures patent protection in the United Kingdom, Germany and France.

Recently, Acinetobacter baumannii, another highly infective pathogen of concern to certain US government interests as well as the government of South Africa, has been defeated by AsepticSure. To date, our AsepticSure technology has defeated every infective pathogen – viral or bacterial – that it has been tested against. Eliminating all infective pathogens from a disinfected space eliminates the infective reservoir, thus rendering the treated space harmless and safe.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]